{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:18:54Z","timestamp":1792592334554,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Autoimmune hepatitis (AIH) is a chronic progressive inflammatory liver disease of immune-mediated origin, which causes long-term liver inflammation and damage. Traditionally, treatment includes azathioprine (AZA) combined with steroids, but recent studies have highlighted mycophenolate mofetil (MMF) as a potential alternative, particularly for patients who do not respond well to AZA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>This study aimed to evaluate the efficacy and safety of MMF versus AZA combined with steroids as first-line treatment for the management of AIH patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A comprehensive systematic review was conducted using the keywords: mycophenolate mofetil, Cellcept, and autoimmune hepatitis. Studies comparing MMF to AZA combined with steroids in treatment-na\u00efve patients with AIH were included. Efficacy was assessed based on complete biochemical remission (CBR), non-response, and relapse rates. Safety was evaluated on the basis of the incidence of serious adverse effects that led to treatment discontinuation. Statistical analysis included calculation of odds ratios (OR) and 95% confidence intervals (CI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Out of 344 search results, four studies met the inclusion criteria, encompassing a total of 512 patients. MMF combined with prednisolone significantly improved both short-term CBR rates (OR, 2.56; 95% CI, 1.18\u20135.55) and long-term CBR rates (OR, 5.51; 95% CI, 1.7\u201317.91) compared to AZA combined with prednisolone. Furthermore, MMF treatment was associated with a significantly lower occurrence of serious adverse events (OR, 0.15; 95% CI, 0.07\u20130.34).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Compared to AZA-based regimens, MMF-based first-line therapy for AIH appears to be a more promising, effective, and safe treatment option, yielding higher CBR rates and fewer serious adverse events requiring treatment discontinuation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12876-025-04206-1","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:59:58Z","timestamp":1755845998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mycophenolate mofetil versus azathioprine as a first-line treatment for autoimmune hepatitis: a comparative systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6155-2819","authenticated-orcid":false,"given":"Amani M.","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0227-8404","authenticated-orcid":false,"given":"Mohamed E.","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1690","authenticated-orcid":false,"given":"Aya M.","family":"AbdelMagid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"4206_CR1","unstructured":"National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). Symptoms & Causes of Autoimmune Hepatitis - NIDDK. Available from: https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/autoimmune-hepatitis\/symptoms-causes. Cited 24 Jun 2024."},{"key":"4206_CR2","unstructured":"Linzay CD, Sharma B, Pandit S. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Autoimmune Hepatitis. 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459186\/."},{"issue":"4","key":"4206_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","volume":"63","author":"European Association for the Study of the Liver","year":"2015","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol. 2015;63(4):971\u20131004.\u00a0Available from:\u00a0https:\/\/doi.org\/10.1016\/j.jhep.2015.06.030.","journal-title":"J Hepatol."},{"key":"4206_CR4","doi-asserted-by":"crossref","unstructured":"Mercado LA, Gil-Lopez F, Chirila RM, Harnois DM. Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview. Diagnostics. 2024;14(4). Available from:\u00a0https:\/\/www.mdpi.com\/2075-4418\/14\/4\/382.","DOI":"10.3390\/diagnostics14040382"},{"key":"4206_CR5","doi-asserted-by":"publisher","unstructured":"Yu ZJ, Zhang LL, Huang TT, Zhu JS, He ZB. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 2019;31(7):873\u20137. Available from: https:\/\/doi.org\/10.1097\/MEG.0000000000001367.","DOI":"10.1097\/MEG.0000000000001367"},{"key":"4206_CR6","doi-asserted-by":"publisher","unstructured":"Dalekos GN, Koskinas J, Papatheodoridis GV. Hellenic association for the study of the liver clinical practice guidelines: autoimmune hepatitis. Ann Gastroenterol. 2024;37(X):1\u201332. Available from: https:\/\/doi.org\/10.20524\/aog.2018.0330.","DOI":"10.20524\/aog.2018.0330"},{"key":"4206_CR7","doi-asserted-by":"publisher","first-page":"102280","DOI":"10.1016\/j.eclinm.2023.102280","volume":"65","author":"JW Hahn","year":"2023","unstructured":"Hahn JW, Yang R, Moon S, Chang Y, Lee K, Kim A, et al. Global incidence and prevalence of autoimmune hepatitis, 1970\u20132022\u202f: a systematic review and meta-analysis. eClinicalMedicine. 2023;65:102280.\u00a0Available from:\u00a0https:\/\/doi.org\/10.1016\/j.eclinm.2023.102280.","journal-title":"eClinicalMedicine"},{"issue":"2","key":"4206_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/hep.32653","volume":"77","author":"T Bittermann","year":"2023","unstructured":"Bittermann T, Lewis JD, Levy C, Goldberg DS. Goldberg DS. Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis. Hepatology. 2023;77(2):367\u201378.\u00a0Available from:\u00a0https:\/\/journals.lww.com\/hep\/fulltext\/2023\/02000\/sociodemographic_and_geographic_differences_in_the.8.aspx.","journal-title":"Hepatology"},{"issue":"2","key":"4206_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","volume":"72","author":"CL Mack","year":"2020","unstructured":"Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671\u2013722. Available from:\u00a0https:\/\/journals.lww.com\/hep\/fulltext\/2020\/08000\/diagnosis_and_management_of_autoimmune_hepatitis.24.aspx.","journal-title":"Hepatology"},{"issue":"43","key":"4206_CR10","first-page":"50","volume":"116","author":"NK Gatselis","year":"2023","unstructured":"Gatselis NK, Zachou K, Loza AJM, Can\u00e7ado ELR, Arinaga-Hino T, Muratori P, et al. Prevalence and significance of antimitochondrial antibodies in autoimmune hepatitis (AIH): Results from a large multicentre study of the International AIH Group. Eur J Intern Med. 2023;116(43):50.\u00a0Available from:\u00a0https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0953620523001978.","journal-title":"Eur J Intern Med"},{"key":"4206_CR11","unstructured":"American Liver Foundation. Autoimmune Hepatitis: Symptoms & Treatments. Available from: https:\/\/liverfoundation.org\/liver-diseases\/autoimmune-liver-diseases\/autoimmune-hepatitis-aih\/. Cited 26 Jun 2024."},{"key":"4206_CR12","unstructured":"National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). Definition & Facts for Autoimmune Hepatitis - NIDDK. Available from: https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/autoimmune-hepatitis\/definition-facts. Cited 24 Jun 2024."},{"key":"4206_CR13","doi-asserted-by":"publisher","unstructured":"Liberal R, Krawitt EL, Vierling JM, Manns MP, Mieli-Vergani G, Vergani D. Cutting edge issues in autoimmune hepatitis. J Autoimmun. 2016;75:6\u201319. Available from: https:\/\/doi.org\/10.1016\/j.jaut.2016.07.005.","DOI":"10.1016\/j.jaut.2016.07.005"},{"key":"4206_CR14","doi-asserted-by":"publisher","unstructured":"Sebode M, Hartl J, Vergani D, Lohse AW. Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda. Liver Int. 2018;38(1):15\u201322.Available from: https:\/\/doi.org\/10.1111\/liv.13458.","DOI":"10.1111\/liv.13458"},{"key":"4206_CR15","doi-asserted-by":"publisher","unstructured":"Zachou K, Gatselis NK, Arvaniti P, Gabeta S, Rigopoulou EI, Koukoulis GK, et al. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Aliment Pharmacol Ther. 2016;43(10):1035\u201347. Available from: https:\/\/doi.org\/10.1111\/apt.13584.","DOI":"10.1111\/apt.13584"},{"key":"4206_CR16","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Available from: https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"4206_CR17","doi-asserted-by":"publisher","unstructured":"Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 2021;10(1):39. Available from: https:\/\/doi.org\/10.1186\/s13643-020-01542-z.","DOI":"10.1186\/s13643-020-01542-z"},{"key":"4206_CR18","doi-asserted-by":"publisher","unstructured":"Hlivko JT, Shiffman ML, Stravitz RT, Luketic VA, Sanyal AJ, Fuchs M, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6(9):1036\u201340. Available from: https:\/\/doi.org\/10.1016\/j.cgh.2008.04.006.","DOI":"10.1016\/j.cgh.2008.04.006"},{"issue":"4","key":"4206_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jhep.2023.11.032","volume":"80","author":"RJALM Snijders","year":"2024","unstructured":"Snijders RJALM, Stoelinga AEC, Gevers TJG, Pape S, Biewenga M, Tushuizen ME, et al. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis. J Hepatol. 2024;80(4):576\u201385. Available from: https:\/\/doi.org\/10.1016\/j.jhep.2023.11.032.","journal-title":"J Hepatol"},{"key":"4206_CR20","doi-asserted-by":"publisher","unstructured":"Hennes EM, Zeniya M, Czaja AJ, Par\u00e9s A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169\u201376. Available from: https:\/\/doi.org\/10.1002\/hep.22322.","DOI":"10.1002\/hep.22322"},{"key":"4206_CR21","doi-asserted-by":"publisher","unstructured":"Zachou K, Gatselis NK, Arvaniti P, Gabeta S, Rigopoulou EI, Koukoulis GK, et al. A real-world study focused on the long\u2010term efficacy of mycophenolate mofetil as first\u2010line treatment of autoimmune hepatitis. Aliment Pharmacol Ther. 2016;43(10):1035\u201347. Available from: https:\/\/doi.org\/10.1111\/apt.13584.","DOI":"10.1111\/apt.13584"},{"key":"4206_CR22","doi-asserted-by":"publisher","unstructured":"Dalekos GN, Arvaniti P, Gatselis NK, Samakidou A, Gabeta S, Rigopoulou E, et al. First results from a propensity matching trial of mycophenolate mofetil vs. Azathioprine in Treatment-Naive AIH patients. Front Immunol. 2022;11(12):798602. Available from: https:\/\/doi.org\/10.3389\/fimmu.2021.798602.","DOI":"10.3389\/fimmu.2021.798602"},{"key":"4206_CR23","doi-asserted-by":"publisher","unstructured":"Dalekos GN, Arvaniti P, Gatselis NK, Gabeta S, Samakidou A, Giannoulis G, et al. Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis. JHEP Reports. 2022;4(12):100601.\u00a0Available from:\u00a0https:\/\/doi.org\/10.1016\/j.jhepr.2022.100601.","DOI":"10.1016\/j.jhepr.2022.100601"},{"key":"4206_CR24","doi-asserted-by":"publisher","unstructured":"Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-na\u00efve patients. J Hepatol. 2011;55(3):636\u201346. Available from: https:\/\/doi.org\/10.1016\/j.jhep.2010.12.032.","DOI":"10.1016\/j.jhep.2010.12.032"},{"issue":"2","key":"4206_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.dld.2018.10.004","volume":"51","author":"G Giannakopoulos","year":"2019","unstructured":"Giannakopoulos G, Verbaan H, Friis-Liby IL, Sangfelt P, Nyhlin N, Almer S. Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine. Dig Liver Dis. 2019;51(2):253\u20137. Available from: https:\/\/doi.org\/10.1016\/j.dld.2018.10.004.","journal-title":"Dig Liver Dis"},{"key":"4206_CR26","doi-asserted-by":"publisher","unstructured":"Roberts SK, Lim R, Strasser S, Nicoll A, Gazzola A, Mitchell J, et al. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy. Clin Gastroenterol Hepatol. 2018;16(2):268\u201377. Available from: https:\/\/doi.org\/10.1016\/j.cgh.2017.09.063.","DOI":"10.1016\/j.cgh.2017.09.063"},{"key":"4206_CR27","doi-asserted-by":"publisher","unstructured":"Ngu JH, Gearry RB, Frampton CM, Stedman CAM. Predictors of poor outcome in patients w Ith autoimmune hepatitis: a population-based study. Hepatology. 2013;57(6):2399\u2013406. Available from: https:\/\/doi.org\/10.1002\/hep.26290.","DOI":"10.1002\/hep.26290"},{"key":"4206_CR28","doi-asserted-by":"publisher","unstructured":"Dettori JR, Norvell DC, Chapman JR. Fixed-Effect vs Random-Effects Models for Meta-Analysis: 3 Points to Consider. Glob Spine J. 2022;12(7):624\u20136. Available from:\u00a0https:\/\/doi.org\/10.1177\/21925682221110527.","DOI":"10.1177\/21925682221110527"},{"key":"4206_CR29","doi-asserted-by":"publisher","unstructured":"Ohira H, Takahashi A, Zeniya M, Abe M, Arinaga-Hino T, Joshita S, et al. Clinical practice guidelines for autoimmune hepatitis. Hepatol Res. 2022;52(7):571\u201385. Available from: https:\/\/doi.org\/10.1111\/hepr.13776.","DOI":"10.1111\/hepr.13776"},{"key":"4206_CR30","doi-asserted-by":"publisher","unstructured":"Dalekos GN, Koskinas J, Papatheodoridis GV. Hellenic association for the study of the liver clinical practice guidelines: autoimmune hepatitis. Ann Gastroenterol. 2019;32(1):1\u201323. Available from: https:\/\/doi.org\/10.20524\/aog.2018.0330.","DOI":"10.20524\/aog.2018.0330"},{"key":"4206_CR31","doi-asserted-by":"publisher","unstructured":"Dalekos G, Gatselis N, Drenth JP, Heneghan M, J\u00f8rgensen M, Lohse AW, et al. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. J Hepatol. 2025.\u00a0Available from:\u00a0https:\/\/doi.org\/10.1016\/j.jhep.2025.03.017.","DOI":"10.1016\/j.jhep.2025.03.017"},{"key":"4206_CR32","doi-asserted-by":"publisher","unstructured":"Santiago P, Schwartz I, Tamariz L, Levy C. Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther. 2019;49(7):830\u20139. Available from: https:\/\/doi.org\/10.1111\/apt.15157.","DOI":"10.1111\/apt.15157"},{"key":"4206_CR33","doi-asserted-by":"publisher","unstructured":"Kolev M, Diem S, Diem L, Rodrigues SG, Berzigotti A, Stirnimann G, et al. Mycophenolate mofetil as second line treatment in autoimmune hepatitis - A retrospective single center analysis. J Transl Autoimmun. 2022;5:100172. Available from: https:\/\/doi.org\/10.1016\/j.jtauto.2022.100172.","DOI":"10.1016\/j.jtauto.2022.100172"},{"key":"4206_CR34","doi-asserted-by":"publisher","unstructured":"Williamson C, Nana M, Poon L, Kupcinskas L, Painter R, Taliani G, et al. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy. J Hepatol. 2023;79(3):768\u2013828. Available from:\u00a0https:\/\/doi.org\/10.1016\/j.jhep.2023.03.006.","DOI":"10.1016\/j.jhep.2023.03.006"},{"key":"4206_CR35","doi-asserted-by":"crossref","unstructured":"Sarkar M, Brady CW, Fleckenstein J, Forde KA, Khungar V, Molleston JP, et al. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73(1).\u00a0Available from:\u00a0https:\/\/journals.lww.com\/hep\/fulltext\/2021\/01000\/reproductive_health_and_liver_disease__practice.25.aspx.","DOI":"10.1002\/hep.31559"},{"key":"4206_CR36","doi-asserted-by":"publisher","unstructured":"Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal free hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut. 1980;21(1):78\u201383. Available from: https:\/\/doi.org\/10.1136\/gut.21.1.78.","DOI":"10.1136\/gut.21.1.78"},{"key":"4206_CR37","doi-asserted-by":"publisher","unstructured":"Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975;16(11):876\u201383. Available from: https:\/\/doi.org\/10.1136\/gut.16.11.876.","DOI":"10.1136\/gut.16.11.876"},{"key":"4206_CR38","doi-asserted-by":"publisher","unstructured":"Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995;333(15):958\u201363. Available from: https:\/\/doi.org\/10.1056\/NEJM199510123331502.","DOI":"10.1056\/NEJM199510123331502"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04206-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04206-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04206-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T19:24:56Z","timestamp":1757445896000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04206-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4206"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04206-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"613"}}